11th Jul 2008 11:07
Annual Information Update 2008
BTG plc (LSE: BGC) ("the Company") is pleased to provide its annual information update, in accordance with the requirements of the Prospectus Rule 5.2. This update refers to information that has been published or made available by the Company to the public over the twelve months ending today. To avoid an unnecessarily lengthy document, information is referred to in this update rather than included in full.
The information referred to in this update was up to date at the time the information was published but some information may now be out-of-date.
(1) Announcements made via RNS, a Regulatory Information Service
All of the documents listed below were published via RNS, a Regulatory Information Service on or around the dates indicated.
|
Date of publication
|
Brief description of announcement |
|
1 July 2008 |
Total voting rights and share capital |
|
16 June 2008 |
Notification of 2008 Annual Report and Accounts and AGM documents filed with UKLA |
|
16 June 2008 |
Block Listing Return |
|
6 June 2008 |
BTG reports successful completion of treatments in Varisolve® US phase II safety study |
|
4 June 2008 |
Acquisition of Protez Pharmaceuticals by Novartis |
|
30 May 2008 |
Total voting rights and share capital |
|
29 May 2008 |
Directors' Interests in shares of BTG plc |
|
19 May 2008 |
Preliminary results statement for the year ended 31 March 2008 |
|
12 May 2008 |
Notice of results |
|
2 April 2008 |
Close period update |
|
31 March 2008 |
Total voting rights and share capital |
|
18 March 2008 |
Notification of major interest in BTG plc shares |
|
17 March 2008 |
Positive interim report of Varisolve® phase II safety study to be presented at SIR 2008 scientific meeting |
|
6 March 2008 |
BTG initiates clinical study of novel multiple sclerosis treatment |
|
29 February 2008 |
Total voting rights and share capital |
|
30 January 2008 |
BTG commences first clinical study of novel migraine treatment |
|
24 January 2008 |
Interim management statement |
|
4 December 2007 |
BTG appoints Dr John Brown as chairman designate |
|
30 November 2007 |
Total voting rights and share capital |
|
19 November 2007 |
Notification of Interim Report and Accounts filed with UKLA |
|
12 November 2007 |
Directors' Interests in shares of BTG plc |
|
7 November 2008 |
Interim results statement for half year ended 30 September 2007 |
|
31 October 2007 |
Total voting rights and share capital |
|
24 October 2007 |
BTG licensee Tolerx forms collaboration with GlaxoSmithKline to develop and commercialise TRX4 |
|
10 October 2007 |
Notification of major interest in BTG plc shares |
|
2 October 2007 |
Notification of major interest in BTG plc shares |
|
28 September 2007 |
Total voting rights and share capital |
|
28 September 2007 |
Close period update |
|
28 September 2007 |
BTG announces Board changes |
|
26 September 2007 |
Campath® commences pivotal phase III trial in multiple sclerosis |
|
20 September 2007 |
Campath® approved for first-line use in adult leukaemia |
|
14 August 2007 |
Notification of major interest in BTG plc shares |
|
31 July 2007 |
Directors' interests in the shares of BTG plc |
|
30 July 2007 |
Block listing application |
|
19 July 2007 |
Directors' interests in the shares of BTG plc |
|
18 July 2008 |
2007 AGM and interim management statement |
|
18 July 2007 |
Results of 2007 AGM |
|
13 July 2007 |
Directors' interests in the shares of BTG plc |
|
12 July 2007 |
Annual Information Update 2007 |
Copies of the above announcements can be downloaded from the Company's website (www.btgplc.com) or obtained from the Company Secretary at the Company's Registered Office, 10 Fleet Place, Limeburner Lane, London, EC4M 7SB.
(2) Documents filed at Companies House
All of the documents listed below were filed with Companies House in Cardiff on or around the dates indicated.
|
Date of filing |
Brief description of document |
|
1 July 2008 |
Form 88(2) allotment of shares re share option exercise |
|
18 June 2008 |
Annual Report and Accounts, year ended 31 March 2008 |
|
30 May 2008 |
Form 88(2) allotment of shares re share option exercise |
|
31 March 2008 |
Form 88(2) allotment of shares re share option exercise |
|
10 March 2008 |
Notification of resignation of Sir Brian Fender as a director |
|
29 February 2008 |
Form 88(2) allotment of shares re share option exercise |
|
8 January 2008 |
Notification of appointment of Dr John Brown as a director |
|
20 December 2007 |
Form 363s Annual Return |
|
30 November 2007 |
Form 88(2) allotment of shares re share option exercise |
|
20 November 2007 |
Form 288b Fred Weiss resignation as a director |
|
31 October 2007 |
Form 88(2) allotment of shares re share option exercise |
|
2 October 2007 |
Form 288a relating to the appointment of Professor Colin Blakemore as a director |
|
2 October 2007 |
Form 288a relating to the appointment of Giles Kerr as a director |
|
28 September 2007 |
Form 88(2) allotment of shares re share option exercise |
Copies of documents filed at Companies House can be obtained from Companies House or obtained from the Company Secretary at the Company's Registered Office, 10 Fleet Place, Limeburner Lane, London, EC4M 7SB. CONTACT:
Andy Burrows
Director of Investor Relations
Telephone: 020 7575 1741
11 July 2008
Related Shares:
BTG